Participated in SonoThera's oversubscribed $125M Series B to advance ultrasound-mediated nonviral genetic medicines into clinical development.
SonoThera is dedicated to developing the next generation of genetic medicines using a proprietary, non-invasive ultrasound-mediated delivery approach that enables broad, highly targeted biodistribution and delivery of diverse genetic payloads without size restriction
SonoThera is dedicated to developing the next generation of genetic medicines using a proprietary, non-invasive ultrasound-mediated delivery approach that enables broad, highly targeted biodistribution and delivery of diverse genetic payloads without size restriction.